What is Monte Rosa Therapeutics, Inc.'s earnings yield?

Monte Rosa Therapeutics, Inc. (GLUE) reported earnings yield of -9.9% in Q1 2026.

What is the long-term trend for Monte Rosa Therapeutics, Inc.'s earnings yield?

Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s earnings yield has grown at a -21.4% compound annual growth rate (CAGR), from -7.8% to -3.8%.

What does earnings yield mean?

Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.

Monte Rosa Therapeutics, Inc. GLUE Earnings yield

Earnings yield at other companies

Bristol-Myers SquibbBMY

5.9%+1.6pp

Nurix Therapeutics, Inc.NRIX

-18%+0.2pp

Kymera TherapeuticsKYMR

-4.6%-1.8pp

ImmunomeIMNM

-9.1%-3.9pp

Cogent Biosciences, Inc.COGT

-5.7%-2.6pp

Adaptive BiotechnologiesADPT

-2.3%-1.0pp

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

net income/market cap=-9.9%

Based on trailing twelve months.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s earnings yield?: Monte Rosa Therapeutics, Inc. (GLUE) reported earnings yield of -9.9% in Q1 2026.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s earnings yield?: Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s earnings yield has grown at a -21.4% compound annual growth rate (CAGR), from -7.8% to -3.8%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.